drug · protein
IMCIVREE
updated 6mo agoby $RYTM RHYTHM PHARMACEUTICALS, INC.🔗 ChEMBL
community read0 votes
🐶 often sniffed alongside
top 2Protein drug with a maximum clinical stage of Approval, with an approval for obesity.
targets
Melanocortin receptor 4
all catalysts(0)
nothing on the calendar yet
News(7)
- Biopharma pushes beyond GLP-1s, weight loss at ObesityWeek 2026ObesityWeek 2026, which kicks off on Saturday, will spotlight presentations on the ascendant amylin pathway, as well as therapies looking to improve the quality of weight loss and patients’ persist…biospace · 4d ago
- Argenx to buy peptide platform in potentially billion-dollar dealFor $550 million up front, Argenx will take control of Unnatural Products’ “macrocyclic peptide” technology and direct it to develop oral, durable medicines for serious immune-mediated diseases.biopharma_dive · 7d ago
- Coveted metabolic gem Rhythm reportedly gets $10B offer from AstraZenecaAstraZeneca has apparently made a $10 billion bid to acquire Rhythm Pharmaceuticals, an offer William Blair suspects will not be the last for the hot ticket metabolic biotech.biospace · 12d ago
- Rhythm doubles down on LG obesity license, raising payout to as much as $855MRhythm Pharmaceuticals and LG Chem have rewritten the terms of their licensing agreement for the oral obesity and hyperphagia drug bivamelagon, growing to $855 million in scheduled payments from th…fiercebiotech · 14d ago
- Novo explores macrocycles’ potential in $1.4B cardiometabolic pact with Danish biotechNovo’s race to rejuvenate its cardiometabolic portfolio has seen the rebranded Danish pharma pen a $1.4 billion biobucks pact with oral macrocycle drug start-up Orbis Medicines.fiercebiotech · 2mo ago
- An AI drug specialist zeroes in on rare forms of obesitySuperluminal Medicines banked $60 million in funding to support development of a drug designed to work similarly to — but potentially be more selectively than — Rhythm Pharmaceuticals’ marketed med…biopharma_dive · 2mo ago
- Chutes & Ladders—Vivace revs up C-suite ahead of pivotal pushVivace Therapeutics has named Craig Gibbs, Ph.D., as its new president and CEO.fiercebiotech · 2mo ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that